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1. Introduction 
The most effective treatment for liver metastases from colorectal cancer is surgical resection. 
When curative resection is possible, a 5-year survival rate of 25% to 58% can be expected; the 
mortality rate associated with surgery is as low as 1% to 5% (Adson et al., 1984; Huges et al., 
1986; Scheele et al., 1995; Nordlinger et al., 1996; Jamison et al., 1997; Iwatsuki et al.,  
1999; Fong et al., 1999; Minagawa et al., 2000; Figueras et al., 2001; Choti et al., 2002; Kato  
et al., 2003; Abdalla et al., 2004; Fernandez et al., 2004; Wei et al., 2006; Rees et al., 2008) 
(Table 1).  
Surgical procedures are improving for liver resection. In cases with synchronous liver 
metastases, resection of primary colorectal cancer with lymph node dissection and liver 
resection were indicated if tumors would be completely removed surgically. In cases with 
metachronous liver metastases, the indication for liver resection was the same as 
synchronous liver metastases if extrahepatic metastases were not detected. More recently, 
experience has demonstrated that patients with the traditional adverse factors can 
experience long-term survival following liver resection (Minagawa et al., 2000; Elias et al., 
2003). Thus, a shift has occurred in the criteria used for assessing resectability, from 
morphologic criteria to new ones based on whether a macroscopically and microscopically 
complete resection of the liver can be achieved. These advancements were reported to 
improve the resectability and survivals of patients. Although evidence from cohort studies 
or randomized controlled trials are not available to support this conclusion, cases of long-
term survival are almost nonexistent among patients who were eligible for surgical resection 
of liver metastases but did not undergo the procedure. Outcomes after hepatectomy are so 
good that studies comparing this treatment with other treatments may be difficult to accept. 
Despite this, recurrence is common after resection of liver metastases. Recurrence in the 
remaining liver occurs with a frequency of 50% to 60%, followed by lung metastasis at 20% 
to 30%, and they occur within the first 2 years after surgery. Based on these observations, 
liver metastasis can be thought of as a local or systemic disease. Thus, improving prognosis 
after resection of liver metastases likely involves controlling local recurrence (in the 
remaining liver) and extrahepatic metastases (primarily lung metastases). However, few 
clinical trials have focused on cases of colorectal cancer after hepatic resection; no adjuvant 
chemotherapy has yet been proven effective in this context. 
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Author Year Number 
of 
patients 
Median survival, 
months 
5 year overall 
survival rate 
Mortality, 
percent 
Adson 1984 141 - 25 4 
Huges 1986 607 - 33 5 
Scheele 1995 350 40 39 4 
Nordlinger 1996 1568 - 28 2 
Jamison 1997 280 33 27 4 
Iwatsuki 1999 305 - 32 1 
Fong 1999 1001 42 37 3 
Minagawa 2000 235 37 38 - 
Figueras 2001 235 46 36 4 
Choti 2002 133 - 58 0 
Kato 2003 585 - 32 - 
Abdalla 2004 190 - 58 - 
Fernadez 2004 100 - 58 - 
Wei 2006 423 - 47 1 
Rees 2008 929 42.5 36 1 
Table 1. Results of hepatic resection for metastatic colorectal cancer 
2. Evidence of adjuvant therapy for resectable liver metastases 
2.1 Hepatic infusion therapy as adjuvant therapy 
Liver metastasis is a local disease limited to the liver. Several comparative studies have 
evaluated the use of hepatic infusion therapy to prevent recurrence in the remaining liver 
before secondary metastasis (e.g., lung metastasis) can occur (Table 2). Lorenz et al. 
conducted a randomized controlled study in Germany with 226 colorectal cancer patients 
who underwent resection of liver metastasis, comparing the efficacy of surgical resection 
alone with that of postoperative adjuvant chemotherapy by hepatic arterial infusion of 5-
fluorouracil (5-FU) (Lorenz et al., 1998). Results of the interim analysis indicated that the 
median survival time (MST) after resection alone was 40.8 months, whereas the MST after 
resection and hepatic arterial infusion chemotherapy was 34.5 months. Because the 
hepatic infusion group had a lower survival rate at the interim analysis, enrollment was 
terminated. This study used the “surgery only” group as the control. Hepatic infusion 
therapy appeared to suppress recurrence in the remaining liver but did not improve 
survival. With the objective of suppressing both recurrence in the remaining liver and 
extrahepatic recurrence, Kemeny et al. conducted a randomized controlled study in the 
United States with 109 colorectal cancer patients after resection of 1 to 3 liver metastases. 
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They compared results of surgical resection alone with those of postoperative hepatic 
arterial infusion with floxuridine (FUDR) in combination with systemic chemotherapy 
with 5-FU (Kemeny et al., 2002). The 4-year disease-free survival rate was 25% for the 
surgery alone group and 46% for the postoperative adjuvant chemotherapy group. 
However, MST did not differ significantly between the two groups (surgery alone, 49.0 
months; postoperative adjuvant chemotherapy, 63.7 months; p=0.60), i.e., adjuvant 
chemotherapy did not prolong survival in this study population. Using a somewhat 
different approach, Kemeny et al. compared two systemic chemotherapies: 5-FU with or 
without leucovorin versus hepatic arterial infusion of FUDR plus 5-FU with or without 
leucovorin. The investigators reported that FUDR combination chemotherapy resulted in 
better 2-year disease-free survival and 2-year survival rates (Kemeny et al., 1999). 
However, none of the studies shown in Table 2 clearly demonstrated that adjuvant 
hepatic arterial infusion chemotherapy is more effective than surgery alone. 
 
Author Year N Regimen 
DFS 
MST, 
months
DFS, 
percent
P 
value
OS 
MST, 
monts
OS, 
percent 
P 
value 
Lorenz 1998 226 no 13.7 0.75 40.8 0.15 
HAI 5FU/LV 14.2 34.5 
Kemeny 2002 109 no 
 
4 year, 
25% 
0.04 49 
 
0.6 
   
5FU+HAI 
FUDR  
4 year, 
46%  
63.7 
  
Kemeny 1999 156 5FU/LV 
 
2 year, 
42% 
0.07 
 
2 year, 
76% 
0.03 
   
5FU/LV+HAI 
FUDR  
2 year, 
57%   
2 year, 
86%  
Table 2. Randomized adjuvant studies comparing HAI with surgery ± systemic 
chemotherapy for resectable liver metastases. HAI=hepatic arterial infusion, DFS=disease-
free survival, OS=overall survival, NS=not significant 
2.2 Systemic chemotherapy as adjuvant therapy 
Few high-quality studies have evaluated the efficacy of systemic chemotherapy as a 
postoperative adjuvant therapy for cases of liver metastasis resection in colorectal cancer. 
One was a randomized controlled study (Portier et al., 2006), and the other was a pooled 
analysis (Mitry et al., 2008) (Table 3).  
Using cases of curative resection, Portier et al. compared outcomes after surgery alone with 
outcomes after 6-month systemic chemotherapy using 5-FU and leucovorin. The 5-year 
recurrence-free survival rate was higher after adjuvant chemotherapy, but overall survival 
did not differ significantly (Portier et al., 2006). Mitry et al. re-analyzed the data from this 
study   and an intergroup study (ENG trial) that had been terminated prematurely due to 
slow subject accumulation. Multivariate analysis showed that chemotherapy consisting of 5-
FU and leucovorin improved life prognosis, but survival time did not differ significantly 
compared with surgery alone (Mitry et al., 2008). 
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Author year 
Number of 
patients 
Regimen 
DFS 
MST, 
months 
P value 
OS 
MST, 
months 
P value 
Portier 2006 171 no 17.6 0.028 46.4 0.13 
5FU/LV 24.4 62.1 
Mitry 2008 302 no 18.8 0.058 47.3 0.095 
      5FU/LV 27.9   62.2   
Table 3. Randomized adjuvant studies comparing systemic chemotherapy with surgery 
alone for resectable liver metastases. DFS=disease-free survival, OS=overall survival 
The European Organization for Research and Treatment of Cancer (EORTC) conducted a 
randomized controlled study (EORTC40983) that enrolled 364 colorectal cancer patients 
with liver metastasis eligible for curative resection (Table 4). The study compared results of 
surgical resection alone with results of surgical resection combined with leucovorin, 5-FU, 
and oxaliplatin (FOLFOX4) chemotherapy administered before and after surgery. The 
results were published in 2008 in The Lancet (Nordlinger et al., 2008). In the subgroup that 
underwent hepatectomy, the 3-year recurrence-free survival rate after hepatectomy was 33% 
for patients who underwent surgery alone and 42% for those who also received adjuvant 
chemotherapy (p=0.025). However, the trial design has been criticized. Although the 
secondary analysis showed significantly improved 3-year progression-free survival with 
adjuvant chemotherapy, the intention-to-treat analysis, which was the main analysis, did 
not show a significant difference. Overall survival time, the true endpoint, has not been 
published. The secondary analysis purportedly demonstrated a significant difference in 
progression-free survival time, but questions have been raised as to how this endpoint was 
defined (Nakamura et.al, 2008). For example, to counteract a clear bias during the 
hepatectomy period for each group, they calculated early events by combining them at a 
single point; the chemotherapy group included cases in which hepatectomy was not 
indicated due to progression of the hepatic lesion or appearance of extrahepatic lesions after 
chemotherapy was initiated. For that reason, interpretation of the results is difficult. 
 
Analysis by treatment 
group 
chemotherapy 
group 
surgery group
difference 
in rate of 
PFS 
HR P value 
N N at 3 years 
All assigned patients 
(ITT analysis) 
182 182 7.2 0.79 0.058 
All eligible patients 171 171 8.1 0.77 0.041 
All resected patients 151 152 9.2 0.73 0.025 
Table 4. Results of EORTC40983 trial. ITT=intention-to-treat, PFS=progression-free survival, 
HR=hazard ratio 
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These data were not sufficient to establish preoperative and postoperative chemotherapy as 
a new standard treatment. Further, the subjects enrolled in EORT40983 were limited to cases 
with no more than four liver metastases, corresponding to the H1 stage of the liver 
metastasis classification of the Japanese Society for Cancer of the Colon and Rectum 
(Kanahara Shuppan, 2009). The H1 stage is the earliest stage of metastasis, comprising fewer 
than half of liver metastasis resection cases encountered in clinical practice (“Study on liver 
metastasis in colorectal cancer,” Project Study by Japanese Society for Cancer of the Colon 
and Rectum, 2004). 
Thus, results of EORTC40983 demonstrated that the perioperative addition of FOLFOX4, a 
potent chemotherapy regimen, could improve prognosis after liver metastasis resection. 
Nevertheless, the optimal method of administering adjuvant therapy has not yet been 
established for liver metastasis resection in colorectal cancer. 
2.3 Preoperative adjuvant chemotherapy for resectable liver metastases 
The National Comprehensive Cancer Network guidelines (http://www.nccn.org) 
recommend multimodality therapy involving hepatectomy and chemotherapy for liver 
metastasis. For resectable liver metastasis, it recommends FOLFOX with or without 
bevacizumab or combined systemic and hepatic arterial infusion therapies after 
hepatectomy. Alternatively, systemic chemotherapy (FOLFOX, FOLFIRI, bevacizumab, 
cetuximab) should be administered before and after hepatectomy.  
2.3.1 Clinical trials of preoperative adjuvant chemotherapy  
To date, no study has reported the effectiveness of preoperative adjuvant chemotherapy for 
cases in which curative hepatectomy is suitable. An aforementioned EORTC40983 study 
(Nordlinger et al., 2008) shows a questionable survival benefit with chemotherapy; however, 
the EORTC40983 trial can be used as a reference.  
2.3.2 Advantage of administering adjuvant chemotherapy before hepatectomy 
What are the advantages of preoperative adjuvant chemotherapy compared with 
postoperative chemotherapy? 
2.3.2.1 Increase in complete (R0) resection due to the shrinkage of liver metastases 
Compared with prognosis after R0 resection, prognosis after incomplete resection (R1, R2) is 
significantly poorer. Charnasangavej et al. reported that cases with positive margins at 
hepatectomy frequently result in local recurrence at the site of resection, leading to poor 
prognosis (Charnasangavej et al., 2006). When liver metastasis foci are large or near the root 
of the hepatic vein or hepatic portal vessel, there is little room to obtain wide margins of 
normal tissue. A diameter greater than 5 cm for liver metastasis is an adverse prognostic 
factor (Kato et al., 2003). If neoadjuvant chemotherapy shrinks the liver metastasis, an 
adequate resection margin is easier to ensure, increasing the likelihood of R0 resection. 
2.3.2.2 Preoperative chemotherapy is more effective at targeting micrometastatic foci and 
suppressing recurrence 
Compared with healthy individuals, patients with liver metastasis from colorectal cancer 
have significantly higher levels of tumor growth factors, including vascular endothelial 
growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), 
and hepatocyte growth factor (HGF). Levels of HGF and bFGF further increase after 
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hepatectomy to promote regeneration of the liver (Yoon et al., 2006). HGF enhances the 
movement and proliferation potential of colorectal cancer cells (Fukuura et al., 1998), and 
other growth factors likely stimulate and expand cancer microfoci. Elimination of cancer 
microfoci with preoperative chemotherapy would prevent recurrence after hepatectomy, 
even in the presence of high levels of growth factors. Tanaka et al. reported that 
preoperative hepatic arterial infusion chemotherapy suppressed microvascular invasion 
near liver metastasis foci in cases of multiple liver metastases in bilateral lobes (Tanaka et 
al., 2004). Therefore, preoperative chemotherapy is expected to exert some suppressive 
effects on micrometastic foci. 
2.3.2.3 Preoperative chemotherapy can be used to evaluate drug sensitivities 
Sensitivity to chemotherapy can be evaluated by computed tomography, magnetic 
resonance imaging studies, or by histologic evaluation of the excised specimen. The most 
effective chemotherapy regimen is thus a strong candidate for postoperative adjuvant 
therapy. Ineffective regimens should not be used for later treatment. 
2.3.2.4 Tolerance to chemotherapy is higher in the preoperative period than the 
postoperative period 
For effective adjuvant chemotherapy, the planned dose should generally be administered 
without dose reduction. Preoperative chemoradiation for rectal cancer is thought to produce 
milder adverse events and a higher completion rate than postoperative treatment (Sauer et 
al., 2004). Similarly, liver metastasis tolerance to chemotherapy may be higher before 
hepatectomy. 
2.3.3 Issues in neoadjuvant chemotherapy 
2.3.3.1 Does neoadjuvant chemotherapy increase postoperative complications due to 
toxicity in normal liver tissue? 
Neoadjuvant chemotherapy combining FOLFOX or FOLFIRI with bevacizumab and/or 
cetuximab exerts a strong tumor cell-killing effect; however, chemotherapy also damages 
normal liver tissue. A high degree of liver damage induced by chemotherapy may cause 
serious postoperative complications after hepatectomy. For example, the EORTC40983 trial 
(Nordlinger et al., 2008) reported that six courses of FOLFOX4 significantly increased 
postoperative complications. When choosing drugs and planning the duration of 
preoperative chemotherapy, a balance must be made between the tumor cell-killing effects 
of treatment and liver damage. Many cases of steatohepatitis were observed after treatment 
with the CPT-11 regimen, and the death rate soon after surgery was high (Vauthery et al., 
2006); therefore FOLFOX is preferred. Results of the EFC2962 trial conducted by De 
Gramont et al., which evaluated progressive and recurrent colorectal cancer not treated with 
chemotherapy, and the V308 trial conducted by Tournigand et al. indicate that it takes about 
2 to 3 months before the effects of FOLFOX therapy begin to appear (de Gramont et al., 2000; 
Tournigand et al., 2004). Neoadjuvant FOLFOX chemotherapy likely requires at least 4 to 6 
courses. 
2.3.3.2 When complete remission (CR) is achieved, resection of liver metastasis foci is 
difficult 
Benoist et al. administered chemotherapy to 586 patients with liver metastasis, and 38 cases 
(6%), or 66 foci, were determined to have achieved CR based on imaging. Post-hepatectomy 
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pathologic examination revealed that 55 of the 66 (83%) foci were viable tumor foci (Benoist et 
al., 2006). Thus, metastatic foci may contain residual viable cancer cells, even if CR is noted on 
imaging; if not removed, residual cancer cells are likely to cause recurrence. Further, the lesion 
that demonstrated CR on imaging after preoperative chemotherapy cannot always be detected 
during surgery. While it is desirable to shrink cancer foci with preoperative chemotherapy, the 
danger is that the lesion cannot be later identified and resected. 
At this point, neither safety nor effectiveness has been established for preoperative 
chemotherapy for resectable liver metastasis. Additional clinical trials will be needed to 
address this issue. 
2.4 Future research  
Surgery and chemotherapy combined can reduce the risk of relapse. However, until recently 
the role of adjuvant chemotherapy in the perioperative setting has been of unclear benefit. 
EORTC40983 trial (Nordlinger et al., 2008) fulfill a profound need for a well done 
randomized trial to compare surgery alone with surgery and chemotherapy for patients 
with resectable colorectal liver metastases. However, their decision to give preoperative 
chemotherapy to patients with resectable colorectal liver metastases, thereby postponing a 
possible curative treatment, can be disputed. Patients who receive preoperative 
chemotherapy increase their chance of postoperative complications, as stated in their report 
(25% vs 16%, p=0.04). Postoperative chemotherapy should theoretically be effective in 
dormant cancer cells in the remnant liver or body. Until the report of the trial by Portier et al 
(Portier et al., 2006), there has been no clear evidence that adjuvant chemotherapy, either 
systemic or by hepatic arterial infusion, added benefit over surgery alone form a 
randomized trial. The results of the trial led by Portier et al (Portier et al., 2006) represents 
that patients receiving postoperative systemic fluorouracil (FU) plus leucovorin (LV) fared 
significantly better than those receiving surgery alone (24.4 months vs 17.6 months, 
respectively) in disease-free survival. However, enrollment to the trial was suspended after 
173 patients due to slow accrual and this trial did not have sufficient statistic power. When 
such trial took 10 years to finish accrual, the original question became outdated since the 
chemotherapy used in it is now considered inferior to currently available regimens 
containing potentially more active agents such as oxaliplatin, irinotecan, bevacizumab or 
cetuximab. Thus, there remains a need for clear evidence for whether combined treatment 
with chemotherapy is better than surgery alone in patients with resectable liver metastases 
from colorectal cancer.  We, therefore, conducted a phase II/III randomized controlled trial 
to evaluate modified FOLFOX (mFOLFOX) as adjuvant chemotherapy for patients with 
curatively resected liver metastases from colorectal cancer. 
The study protocol was designed by the Colorectal Cancer Study Group (CCSG) of the 
Japan Clinical Oncology Group (JCOG), approved by the Protocol Review Committee of 
JCOG on 15 February 2007. This trial was registered as JCOG0603 study (Kanemitsu et al., 
2009) at the UMIN Clinical Trials Registry as UMIN000000653 
(http://www.umin.ac.jp/ctr/index.htm). 
2.4.1 Digest of the JCOG0603 study protocol  
2.4.1.1 Purpose 
To evaluate systemic intravenous adjuvant chemotherapy in comparison with observation 
alone after curative resection of liver metastases from colorectal cancer (Fig. 1). 
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Fig. 1. JCOG0603 study scheme 
2.4.1.2 Study setting 
A multi-institutional prospective randomized controlled trial, with participating institutions 
including 39 specialized centers as of 4 September 2008. 
2.4.1.3 Resources 
Health and Labour Sciences Research Grants for Clinical Research for Evidenced Based 
Medicine, Clinical Cancer Research and Grants-in-Aid for Cancer Research (17S-3, 17S-5), 
from the Ministry of Health, Labour and Welfare, Japan. 
2.4.1.4 Endpoints  
The primary endpoint is treatment compliance at 9 courses after beginning mFOLFOX 
(bolus and infusion FU and LV with oxaliplatin) in phase II and is disease-free survival in 
phase III, respectively. Secondary endpoints are overall survival, incidence of adverse 
events defined by Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0 and 
mode of recurrence after liver resection. 
2.4.1.5 Eligibility criteria  
Primary tumors are staged according to the sixth edition of the tumor-nodes-metastasis 
(TNM) classification system of the Union International Contre Cancer (UICC).  
2.4.1.6 Inclusion criteria  
Prior to entry to the study, the patients must fulfill the following criteria: 
i. histologically proven adenocarcinoma of the colorectum. 
ii. Complete macroscopic and microscopic (R0) resection of both primary and secondary 
lesions. 
iii. No extrahepatic disease. 
iv. No prior chemotherapy except oxaliplatin or radiotherapy within 3 months preceding 
registration. 
v. No prior radiofrequency ablation or cryotherapy for liver metastasis. 
vi. At 42 to 70 days after hepatectomy. 
vii. Age ranging between 20 and 75 years old. 
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viii. Preoperative ECOG performance status 0-1. 
ix. Sufficient organ functions before chemotherapy. 
x. Written informed consent. 
2.4.1.7 Exclusion criteria  
Exclusion criteria are as follows: (i) synchronous or metachronous cancer; (ii) pregnancy; 
(iii) psychological disorder; (iv) steroid administration; (v) patients must use flucytosine, 
phenytoin or warfarin potassium; (vi) insulin dependent or uncontrollable diabetes mellitus; 
(vii) diarrhea or peripheral neuropathy greater than grade 1 and (viii) medical history of 
allergy or hypersensitivity to any drug.  
2.4.1.8 Registration  
Using telephone or fax to the JCOG Data Center, eligible patients between 42 and 70 days 
after liver surgery are registered centrally and assigned randomly by the minimization 
method of balancing the arm according to the synchronous or metachronous metastases to 
the liver, the number of metastases, the largest size of metastases, number of metastatic 
lymph nodes in the primary lesion and institution.  
2.4.1.9 Treatment Methods (Fig. 2)  
Enrolled patients are assigned to surgery alone (arm A, control group) or to mFOLFOX6 and 
surgery (arm B, treatment group). In arm B, adjuvant treatment is started between 56 and 84 
days after liver surgery. Chemotherapy consisted of an intravenous injection of oxaliplatin 
85mg/m2 with l-LV 200mg over 2 hours plus 5FU 400mg/m2 bolus and 2400mg/m2 
continuous infusion over 46 hours every 2 weeks. This cycle is repeated for 12 courses in the 
absence of disease progression or unacceptable toxicity. 
 
 
l-Leucovorin 
200mg/m2 
d.i.v. 
Oxaliplatin 
85mg/m2 
d.i.v. 
5-fluorouracil 
2400mg/m2 
48hr. Continuous d.i.v. 
5-fluorouracil 
400mg/m2 
Bolus i.v. 
2 hours 48 hours 
Day1 Day2 Day3 
 
 
Fig. 2. Treatment schedule in postoperative chemotherapy arm 
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3. Conclusion 
To date, no studies have demonstrated that adjuvant chemotherapy before or after radical 
resection clearly improves life prognosis for patients with liver metastasis from colorectal 
cancer. After EORTC40983, regimens involving strong preoperative chemotherapy 
attracted attention. However, preoperative chemotherapy increases the risk of hepatic 
dysfunction and postoperative complications. Thus, doubt has been raised regarding the 
use of preoperative adjuvant chemotherapy for resectable liver metastasis. Furthermore, 
hepatectomy may become impossible if the tumor grows because preoperative 
chemotherapy is ineffective or if target lesions disappear in cases of complete response. 
To improve outcomes for cases of resectable liver metastasis, postoperative adjuvant 
therapy strategies may be useful; however, there is insufficient evidence to recommend 
postoperative adjuvant therapy in clinical practice. This therapy should be considered 
experimental, and participation in a clinical trial is recommended to obtain high-level 
evidence. The Japan Clinical Oncology Group initiated a comparative study of surgery 
alone versus FOLFOX6 after curative resection of liver metastasis from colorectal cancer 
(JCOG0603). The active drugs (5-FU, CPT-11, oxaliplatin, and the molecular-targeted 
drugs bevacizumab and cetuximab) are available for use. In addition, the EORTC40983 
trial suggested the usefulness of perioperative chemotherapy. Although the efficacy of 
these treatments has not yet been fully established, the use of adjuvant therapy before 
and/or after hepatectomy may be increasing. Opinion leaders in the world acknowledge 
that a no-treatment group control arm is necessary to obtain highly accurate study results 
(Alberts et al., 2006); however, the difficulty of enrolling patients in past trials (Langer et 
al., 2002; Portier et al., 2006) has lead to study designs that no longer include a no-
treatment group. This has hampered the accumulation of evidence supporting adjuvant 
chemotherapy in liver metastasis resection in colorectal cancer (Alberts et al., 2006). 
Combination chemotherapy has improved outcomes for colorectal cancer, but studies of 
adjuvant therapy for cases of liver metastasis resection in colorectal cancer are 
increasingly designed with technical rather than scientific considerations in mind. The no-
treatment control group in the JCOG0603 trial allowed high-level evidence to be obtained, 
and the significance of these results is unquestionable. On the other hand, EORTC40983 
presented ambiguous results. We conclude that the JCOG0603 trial is the only 
randomized controlled trial that may be able to clarify the effectiveness of postoperative 
adjuvant chemotherapy when liver metastasis is completely resected. We eagerly await 
the results of this trial. 
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